13F Pro Quality Score
Below size threshold
Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $20.3M in revenue and is scored on the micro-cap board instead.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
Reported revenue, net income and operating margin by fiscal year, from Cellyan Biotechnology Co., Ltd's annual filings on SEC EDGAR.
| Period | Form | Revenue | Net income | Op. marginOperating margin |
|---|---|---|---|---|
| FY 2026 | 20-F | $13.4M | $-1.1M | -17.8% |
| FY 2025 | 20-F | $20.3M | $-27.1K | -11.3% |
| FY 2024 | 20-F | $16.7M | $1.3M | -11.7% |
| FY 2023 | 20-F | $12.6M | $998.2K | -14.3% |
Cellyan Biotechnology Co., Ltd (HKPD) stock profile, AI quality score, and SEC EDGAR financial data, a Consumer Staples sector company. HKPD is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $20.3m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (FY 2026), Cellyan Biotechnology Co., Ltd reports quarterly revenue of $13.4M, net income of $-1.1M, an operating margin of -17.8%. HKPD trades on the Nasdaq exchange and files with the SEC under CIK 2007702. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate HKPD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Cellyan Biotechnology Co., Ltd directly from SEC EDGAR.